In these two podcasts, medical experts and a patient representative share their perspectives on new Primary Biliary Cholangitis (PBC) data from EASL 2023.
In podcast 1, physicians Dr Emma Culver and Prof. Gideon Hirschfield discuss the evidence of cancer risk associated with PBC, how liver stiffness progression is associated with prognosis; and outcomes and response prediction in second-line therapy.
In podcast 2, CEO of the PBC Foundation, Robert Mitchell-Thain, and autoimmune specialist nurse Kath Houghton explore the impact of PBC symptoms and new instruments for assessing them. They also discuss data highlighting the importance of the current move toward normalisation of liver biomarkers and take a look at some early data on future therapies and therapeutic targets.
Transcripts, with details of the presentations covered, are available for download.